UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

Date of Report: June 22, 2021

Commission File Number: 001-39307

Legend Biotech Corporation (Exact Name of Registrant as Specified in its Charter)

2101 Cottontail Lane Somerset, New Jersey 08873 (Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F 🗵 Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): 🗆

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): 🗆

Legend Biotech Announces Advancement of Global Manufacturing Infrastructure and Updates Corporate Presentation

On June 22, 2021, Legend Biotech Corporation ("Legend Biotech") issued a press release relating to the advancement of its global manufacturing infrastructure.

On June 22, 2021, Legend Biotech also posted an updated version of its corporate presentation, reflecting updates to its product candidate pipeline and manufacturing infrastructure, to its website.

The press release is attached to this Form 6-K as Exhibit 99.1 and the corporate presentation is attached to this Form 6-K as Exhibit 99.2.

EXHIBIT INDEX Exhibit Title

99.1Press Release, dated June 22, 2021.99.2Corporate Presentation – June 2021

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

LEGEND BIOTECH CORPORATION

(Registrant)

By:

/s/ Ying Huang Ying Huang, Ph.D. Chief Executive Officer and Chief Financial Officer

June 22, 2021



Legend Biotech Announces Advancement of Global Manufacturing Infrastructure

New Cell Therapy Facility in Belgium Establishes Manufacturing Presence in the European Union

New facility builds upon Legend Biotech's collaboration with Janssen to advance the manufacturing of investigational CAR-T therapy ciltacabtagene autoleucel (cilta-cel), being developed for the treatment of multiple myeloma

SOMERSET, N.J.— June 22, 2021— Legend Biotech Corporation (Legend Biotech, NASDAQ: LEGN), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, announced the establishment of a state-of-the-art manufacturing facility in Belgium, as part of a joint investment with Janssen Pharmaceutica NV (Janssen), to expand global manufacturing capacity of innovative cellular therapies.

Legend has a collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize cilta-cel, an investigational CAR-T therapy currently under review by several health authorities around the world including the United States and Europe for the treatment of patients with relapsed and refractory multiple myeloma.

"The new location in Belgium is an ideal choice for Legend to launch our European manufacturing presence allowing us to tap into the area's vast talent pool and leverage the strong Belgian life sciences ecosystem," said Liz Gosen, Senior Vice President, Global Technical Operations. "We are excited to expand our existing robust manufacturing network to support the production and delivery of cilta-cel for patients across the globe."

This facility adds to Legend's existing manufacturing facilities and presence in Nanjing, China and in Raritan and Somerset, N.J., U.S. The facility is anticipated to be operational by 2023.

About Legend Biotech

Legend Biotech is a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications. Our team of over 900 employees across the United States, China and Europe, along with our differentiated technology, global development, and manufacturing strategies and expertise, provide us with the strong potential to discover, develop, and manufacture best-in-class cell therapies for patients in need.

We are engaged in a strategic collaboration to develop and commercialize our lead product candidate, cilta-cel, an investigational BCMA-targeted CAR-T cell therapy for patients living with multiple myeloma. This candidate is currently being studied in registrational clinical trials.

About Ciltacabtagene autoleucel (cilta-cel)

Cilta-cel is an investigational chimeric antigen receptor T cell (CAR-T) therapy that is being studied in a comprehensive clinical development program for the treatment of patients with multiple myeloma. Cilta-cel is a differentiated CAR-T therapy with two BCMA-targeting single domain antibodies. In December 2017, Legend Biotech, Inc. <u>entered</u> into an exclusive worldwide license and collaboration agreement with Janssen Biotech, Inc. to develop and commercialize cilta-cel. In addition to a Breakthrough Therapy Designation (BTD) <u>granted</u> in the U.S. in December 2019, cilta-cel received a <u>BTD</u> in China in August 2020. Orphan Drug Designation was granted for cilta-cel by the U.S. FDA in February 2019, and by the European Commission in February 2020. Applications seeking approval of cilta-cel for the treatment of patients with relapsed/refractory multiple myeloma are currently under regulatory review by several health authorities around the world including the United States and Europe.

Cautionary Note Regarding Forward-Looking Statements

Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the development of Legend Biotech's manufacturing infrastructure, including construction of new facilities. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the factors discussed in the "Risk Factors" section of the Annual Report filed with the Securities and Exchange Commission on April 2, 2021. Any forward-looking statements contained in this press release speak only as of the date hereof, and Legend Biotech specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Readers should not rely upon the information on this page as current or accurate after its publication date.

Media and Investor Relations:

Jessie Yeung, Head of Corporate Finance and Investor Relations, Legend Biotech jessie, yeung@legendbiotech.com or investor@legendbiotech.com

Crystal Chen, Manager of Investor Relations and Corporate Communications, Legend Biotech crystal.chen@legendbiotech.com or media@legendbiotech.com

Source: Legend Biotech

Inspired by the **human element** to advance cell therapy

June 2021





Disclaimer

This presentation has been prepared by Legend Biotech Corporation ("Legend Biotech" or the "Company") solely for information purpose and does not contain all relevant information relating to the Company.

The safety and efficacy of the agents and/or uses under investigation discussed in this presentation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.

Certain information contained in this presentation and statements made orally during this presentation relate to or are based on studies, publications, surveys and other data obtained from third-party sources and Legend Biotech's own internal estimates and research. While Legend Biotech believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. While Legend Biotech believes its internal research is reliable, such research has not been verified by any independent source.

Forward-Looking Statements

This presentation contains "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

These forward-looking statements include, but are not limited to, statements relating to the Company's strategies and objectives; the anticipated timing of, and ability to progress, clinical trials; the ability to make, and the timing of, regulatory submissions in the United States, Europe and Asia, including Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA) for citta-celt to the European Medicines Agency (EMA), and the submission of an Investigational New Drug (IND) for LB1901 in relapsed or refractory T-Cell Lymphoma (TCL); the ability to generate, analyze and present data from clinical trials; patient enrollment; anticipated timing regarding regulatory approvals by the FDA, EMA or Center for Drug Evaluation (CDE); and the potential benefits of Legend Biotech's product candidates. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Legend Biotech's product candidates. Actual results may differ materially from those indicated by such forward-looking statements or delays, including requests for additional safety and/or efficacy data or analysis of data, or government regulation generally, unexpected delays as a result of actions undertaken, or failures to act, by our third party partners; uncertainties arising from challenges to Legend Biotech's product in response to the evolving and other political pressures; the duration and severity of the COVID-19 pandemic and government and regulatory measures implemented in response to the evolving situation; as well as the other factors discussed in the "Risk Factors" section of the Company's Annual Report filed with the Securities and Exchange Commission on April 2, 2021.

Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in this presentation as anticipated, believed, estimated or expected.

Any forward-looking statements contained in this presentation speak only as of the date of this presentation. None of the Company nor any of its affiliates, advisers, or representatives has any obligation and does not undertake to update any forward-looking statements to reflect future events or circumstances.



Legend Highlights






We Are A Fully Integrated Global Cellular Therapy Company




RRMM, Relapsed and/or Refractory Multiple Myeloma; AML, acute myeloid leukemia; KOL, key opinion leaders *Legal entity to the agreement is Janssen Biotech, Inc.


Legend Biotech's Global R&D Strategy




End-to-End R&D Capability




Robust Pipeline of the Next Generation Cell Therapies



*In collaboration with Janssen, Pharmaceutical Companies of Johnson & Johnson *LEGEND-2 trial is completed with ongoing follow-up LEGEND BLOTECH




Highly Experienced Management Team





Multiple Myeloma: Blood Cancer with a High Unmet Need



First-in-Human, Phase 1, Dose Finding Study in RRMM LEGEND-2: LCAR-B38M CAR-T cells




Data out-off: 31 July 2019 (N=57) and 31 October 2019 (N=17); 1. Wang B-Y et al. ASH Annual Meeting; December 7-10, 2019; Orlando, FL, Abstract 579. 2. Chen L, et al. ASH Annual Meeting; December 7-10, 2019; Orlando, FL, Abstract 1858.

Administered dose (CAR+ viable T cells/kg)



LEGEND-2: Long-Term Deep Responses and High Response Rate



LEGEND

Data cut-off: 31 July 2019 (N=57) and 31 October 2019 (N=17): X'an: NE patient died of PE/ACS prior to first evaluation. RJ.JS, CZ: For NE patients, 1 patient died on Day 13 due to CRS and tumor lysis syndrome; 1 patient received ohemotherapy prior to first assessment and was censored. «ORR=PR or better; response assessed per International Myelonia Working Group oriteria CR, complete response; VGPR, very good partial response; PR, partial response; SD, stable disease; PD, progressive disease; NE, not evaluable; mDOR, median duration of response; MRD, minimal residual disease; ORR, overall response rate; mPFS, median progression free survival; mOsrall survival. 1. Wang B-Y et al. ASH Annual Meeting; December 7-10, 2019; Orlando, FL, Abstract 579; 2. Chen L, et al. ASH Annual Meeting; December 7-10, 2019; Orlando, FL, Abstract 1858.

CARTITUDE-1: Phase 1b/2 Study Design

Primary Objectives

- Phase 1b: Characterize the safety of ciltacabtagene autoleucel (cilta-cel) and confirm the recommended phase 2 dose
- Phase 2: Evaluate the efficacy of cilta-cel by ORR

Key Inclusion Criteria

- Progressive MM per IMWG criteria
- ECOG PS≤1
- Measurable disease
- Received ≥3 prior therapies or double refractory
- Prior PI, IMiD, anti-CD38 therapy

Administered dose

Median administered dose: 0.71x106 (0.51-0.95x106) CAR+ viable T cells/kg

Screening (28 Days) Apheresis Bridging Therapy^a (as needed) Day -5 to -3 Cy (300 mg/m²) + Flu (30 mg/m²) Cilta-cel Infusion Target: 0.75x10⁶ (0.5 – 1.0x10⁶) CAR+ viable T cells/kg Day 1 **Post-infusion Assessments** Safety, Efficacy, PK, PD, Biomarker Follow-up

CARTITUDE •1

Cy, cyclophosphamide; ECOG PS, Eastern Cooperative Oncology Group performance status; Flu, fludarabine; IMiD, immunomodulatory drug; IMWG, International Myeloma Working Group; PI, proteasome inhibitor; PD, pharmacodynamic; PK, pharmacokinetic; MM, multiple myeloma Data cut-off: Feb 11, 2021; "Treatment that was received previously and resulted in at least stable disease. 1. Usmani S, et al. ASCO Annual Meeting (Virtual). June 4-8, 2021. Abstract 8005; 2. Clinicaltrials.gov website (NCT03548207). https://clinicaltrials.gov/ct2/show/NCT03548207. Accessed June 2021 (CLEGEND


CARTITUDE-1: Baseline Characteristics

Characteristic (N=97)		Characteristic	
Age, median (range) years	61.0 (43–78)	Prior lines of therapy, median (range)	6.0 (3–18)
Male, n (%)	57 (58.8)	Prior lines of therapy, n (%)	
Black/African American, n (%)	17 (17.5)	3	17 (17.5)
All plasmacytomas, ^a n (%)	19 (19.6)	4 ≥5	16 (16.5) 64 (66.0)
Extramedullary plasmacytomas, n (%)	13 (13.4)	Previous stem-cell transplantation, n (%)	
Bone-based plasmacytomas, n (%)	6 (6.2)	Autologous	87 (89.7)
Bone-marrow plasma cells ≥60%, n (%)	21 (21.9)	Allogeneic Triple-class exposed, ^c n (%)	8 (8.2) 97 (100)
Years since diagnosis, median (range)	5.9 (1.6-18.2)	Penta-drug exposed, ^d n (%)	81 (83.5)
High-risk cytogenetic profile, n (%)	23 (23.7)	Triple-class refractory ^c	85 (87.6)
del17p	19 (19.6)	Penta-drug refractory ^d	41 (42.3)
t(14;16)	2 (2.1)	Refractory status, n (%) Carfilzomib	62 (64 0)
t(4;14)	3 (3.1)	Pomalidomide	63 (64.9) 81 (83.5)
Tumor BCMA expression ≥50%, n (%)	57 (91.9) ^b	Anti-CD38 antibody	96 (99.0)
na manana na ana ao amin'ny sorana amin'ny tanàna dia mampika mandritra dia mampika mandritra dia mandritra dia		Refractory to last line of therapy, n (%)	96 (99.0)

Data cut-off: Feb 11, 2021; BCMA, B-cell maturation antigen; IMiD, immunomodulatory drug; PI, proteasome inhibitor. "All plasmacytomas include extramedullary and bone-based plasmacytomas. "Denominator n=62, the number of evaluable samples; BCMA expression detected in all evaluable samples. "At least 1 PI, at least 1 IMiD, and 1 anti-CD38 antibody. "At least 2 INiDs, and 1 anti-CD38 antibody. Usmani S, et al. ASCO Annual Meeting (Virtual). June 4-8, 2021. Abstract 8005 LEGEND BIOTECH

1


CARTITUDE-1: Overall Response Rate



Data cut-off. Feb 11, 2021; CR, complete response; MRD, minimal residual disease; ORR, overall response rate; sCR, stringent complete response; VGPR, very good partial response. ORR assessed by independent review committee. "Subgroups by number of prior lines of therapy (≤4, +4), infractoriness (triple-class, penta-drug), cytogenetic risk (high risk, standard risk), baseline bone marrow plasma cells (<30%, >30 to <50%, e30%), baseline tumor BCMA expression (semedian, "amedian), and baseline plasmacrychmas (including extramedullary and bone-based). "MRD was assessed in evaluable samples (ie, patients with identifiable clone at baseline and sufficient cells for testing at 10 °th reshold in posttreatment samples) by next-generation sequencing (clonoSEQ, Adaptive Biotechnologies) in all treated patients at Day 28, and at 6, 12, 18, and 24 months regardless of the satus of disease measured in blood or urine. Usmani S, et al. ASCO Annual Meeting (Virtual). June 4-8, 2021. Abstract 8005



CARTITUDE-1: Progression Free Survival



Data cut-off: Feb 11, 2021; NE, not estimable; PFS, progression-free survival; OS, overall survival; sCR, stringent complete response. Usmani S, et al. ASCO Annual Meeting (Virtual). June 4-8, 2021. Abstract 8005

CARTITUDE-1: Safety

	N = 97	
	Any Grade	Grade 3/4
Hematologic AEs, (≥30%), n (%)		
Neutropenia	93 (95.9)	92 (94.8)
Anemia	79 (81.4)	66 (68.0)
Thrombocytopenia	77 (79.4)	58 (59.8)
Leukopenia	60 (61.9)	59 (60.8)
Lymphopenia	51 (52.6)	48 (49.5)
Non-hematologic AEs (≥30%), n (%)	
Hypocalcemia	31 (32.0)	3 (3.1)
Hypophosphatemia	30 (30.9)	7 (7.2)
Fatigue	36 (37.1)	5 (5.2)
Cough	34 (35.1)	0
CAR-T associated AEs, n (%)		
CRSª	92 (94.8)	4 (4.1)
Neurotoxicity	20 (20.6)	9 (9.3)

No new safety signals with longer follow-up

CRS

- 94.6% of patients experienced low-grade CRS (n=92)
- Median time to onset of 7 days (range, 1-12)
- Median duration of 4 days (range, 1-97)^b and resolved in 91 (98.9%) patients within 14 days of onset


Neurotoxicity

- 20.6% of patients experienced neurotoxicity in total with overlap between ICANS and Other Neurotoxicities (Grade ≥3: 10.3%)
 - ICANS observed in 16.5% (Grade $\geq\!\!3:2.1\%)$
 - Other Neurotoxicities° observed in 12.4% (Grade ≥3: 9.3%)
- 6 treatment-related deaths as assessed by the investigator^d

19


Data cut-off: Feb 11, 2021; AE, adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ASTCT, American Society for Transplantation and Cellular Therapy; CRS, cytokine release syndrome; HLH, hemophagocytic lymphohisticytosis. *CRS was graded using Lee et al. (*Blood* 2014) in the phase 1b portion of the study and ASTCT in phase 2; in this combined analysis, Lee et al. criteria were mapped to ASTCT criteria for patients in the phase 1b portion. *The patient with 97-day duration died due to CRS/HLH. *Events not reported as ICANS (ie, onset after a period of recovery from CRS and/or ICANS). *There were 21 study deaths: 6 were treatment (n=5) and disease progression (n=10) Usmani S, et al. ASCO AnnualMeeting (Virtual). June 4-8, 2021. Abstract 8005

CARTITUDE-2: Multicohort Study Cohort A: 1 – 3 prior lines, lenalidomide refractory RRMM



CARTITUDE-2: Phase 2 Multi-Cohort Study

Cohort A included 20 patients who had progressive MM after 1-3 prior lines of therapy and were refractory to lenalidomide Median prior lines of therapy: 2 (range, 1-3); 1 patient treated in an outpatient setting




Data cut-off date: Jan 2021; "Patient who did not respond had stable disease. ^HMRD was assessed in evaluable samples (ie, patients with identifiable clone at baseline and sufficient cells for testing at 10 ^s threshold in post treatment samples) by next-generation sequencing (clonoSEQ, Adaptive Biotechnologies) in all treated patients. CR, complete response; MRD, minimal residual disease; ORR, overall response rate; PR, partial response; sCR, stringent complete response; TEAE, treatment-emergent adverse events; VGPR, very good partial response. Agha M, et al. ASCO Annual Meeting (Virtual). June 4-8, 2021. Abstract 8013.



CARTITUDE Program: Safety


Successful new patient management strategies have been implemented in the CARTITUDE program to prevent and reduce the incidence of neurotoxicity¹⁻³



AE, adverse event; CRS, cytokine release syndrome; ICANS, immune effector cell-associated neurotoxicity syndrome; TEAE, treatment-emergent AE. "Two patients with ongoing symptoms continued to improve at the time of data cutoff; patient management strategies were implemented, including enhanced bridging therapy to reduce baseline tumor burden, early aggressive treatment of CRS and ICANS, handwriting assessments for early detection of neurotoxicity symptoms, and extended monitoring and reporting time for neurotoxicity beyond the first 100 days post-cilita-cellinfusion. "Defined as having high tumor burden when any of the following parameters were met bone marrow plasma cell 830%, serum M-spike ≥ 5 g/dL, serum free light chain \geq 500 mg/L. "Included patients treated in earlier and later line settings 1. Usmani S, et al. ASCO Annual Meeting (Virtual). June 4-8, 2021. Abstract 8005. 2. Agha M, et al. ASCO Annual Meeting (Virtual). June 4-8, 2021. Abstract 8013. 3. Einsele H, et al. ASCO Annual Meeting (Virtual). June 4-8, 2021. Abstract 8028



Clinical Program: Cilta-cel Studies in Multiple Myeloma



Global Manufacturing Footprint









Future Potential Milestone Payments

Clinical Milestones: \$105M

\$105 million for the achievement of specified future development milestones

Regulatory Milestones: \$710M

\$710 million for the achievement of specified regulatory milestones

Commercial Milestones: \$210M

\$210 million for the achievement of specified net trade sales milestones.

Manufacturing Milestones: \$125M

Further milestone payments of up to \$125 million for the achievement of specified manufacturing milestones



Future Potential Milestones

Program Areas of Development

Legend Biotech is utilizing the extensive cell therapy experience of our leadership and R&D staff, global clinical partners, and expanding research facilities to realize the potential of cell therapy to treat diseases that are thought to be incurable, such as hematologic malignancies, solid tumors and infectious diseases.




LB1901: Investigational CAR-T for T Cell Lymphoma

MoA/ Scientific Rationale	 LB1901 targets CD4 antigen that is expressed in most T cell lymphoma (TCL) subtypes and in subsets of normal immune cells LB1901 is a CD8-enriched anti-CD4 CAR-T and contains a unique binder to CD4 leading to potential elimination of CD4+tumor cells
Target	 CD4 is a surface membrane glycoprotein expressed at high levels on TCL and a subtype of normal T cells¹ Anti-CD4 mAb have been investigated in clinical studies for TCL²
Clinical Development	 US IND cleared with FDA Ongoing Phase 1 studies in US and China Patient population: relapsed/refractory PTCL and CTCL patients

CD, cluster of differentiation; CAR, chimeric antigen receptor; CTCL, cutaneous T-cell lymphoma; FDA, Food & Drug Administration; IND, investigational new drug application; mAb, monoclonal antibody; PTCL, peripheral T-cell lymphoma 1. Scherer LD, et al. Front Oncol. 2019;9:126; 2. Knox S, et al. Blood. 1996;87:893-899.



LB1908: Investigational CAR-T for Gastric Cancer



1. Zhang J, et al. Chin J Cancer Res. 2020 Apr;32(2):263-70. 2. Sahin U, et al. Clin Cancer Res. 2008 Dec 1;14(23):7624-34.




LB1905: Investigational Allogenic CAR-T

MoA/ Scientific Rationale	 LB1905 targets CD20 that is expressed in B cell lymphoma LB1905 applied Legend UniCAR technology which is an unique non-gene- editing allogeneic CAR-T platform Simple and efficient manufacturing promote product homogeneity and accessibility
Target	• CD20 is mainly expressed in pre-B cells and mature B cells. It is expressed in more than 95% of B-cell lymphomas and not in hematopoietic stem cells, plasma cells, and other normal tissues
Clinical Development	 Allogeneic CD20 targeted product for the treatment of adult patients with recurred NHL Promising allogeneic platform that can potentially be leveraged in Legend clinical development programs

ELEGEND 29

Near-Term Targets for Legend Biotech



Investment Highlights



Global Collaboration

Global collaboration with Janssen for the development of cilta-cel with ongoing clinical trials

Promising Clinical Data

Deep and durable anti-tumor responses observed in heavily pretreated patients with MM; BLA for cilta-cel submitted to US FDA (PDUFA target action date Nov 29, 2021); MAA for cilta-cel submitted to EMA

Fully Integrated Platform

End-to-end R&D and manufacturing capabilities with two core technologies (CAR and TCR) and two platforms (Autologous and Allogeneic)




Experienced team with broad involvement in biopharmaceutical drug discovery, development and commercialization

31

BLA: Biologics License Application; FDA: Federal Drug Administration; PDUFA: Prescription Drug User Fee Act; MAA: Marketing Authorization Application; EMA: European Medicines Agency

LEGEND



We are bridging the gap between **East and West**.



Thank You !

